The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.

摘要

The tyrosine kinase inhibitor (TKI) imatinib is the first-line treatment for chronic myeloid leukemia (CML). However, approximately 30% of patients need a more effective therapy within 5 years of the diagnosis of CML [1]. Dasatinib is a novel multi-targeted TKI that is used for the treatment of imatinib-resistant or imatinib-intolerant patients with CML in any phase of the disease [2]. The main side effects of this drug include myelosuppres-sion, pleural effusions, bleeding, rashes, and fatigue [3]. Subcutaneous nodules have not been reported. We report a 71-year-old man with chronic-phase CML who developed colonic ulcers, subcutaneous nodules, and pleural effusion after treatment with dasatinib.